Status:
COMPLETED
Staccato Prochlorperazine in Migraine (in Clinic)
Lead Sponsor:
Alexza Pharmaceuticals, Inc.
Conditions:
Migraine Headache, With or Without Aura
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
Development of Staccato Prochlorperazine for the treatment of migraine headache.
Eligibility Criteria
Inclusion
- Subjects who have migraine headache with or without aura (diagnosis according to International Headache Society guidelines) for at least 6 months, who have been pain free for at least 48 hours since the end of their last migraine attack, who have a pain rating of Moderate or Severe prior to dosing.
Exclusion
- Subjects who have taken any other migraine or pain medication within 48 hours of randomization, with a history of allergy or intolerance to phenothiazines and related drugs, or are considered by the investigator, for any reason, to be an unsuitable candidate for receiving prochlorperazine, or unable to use the inhalation device, must be excluded.
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2005
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT00610428
Start Date
March 1 2005
End Date
October 1 2005
Last Update
January 25 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Arthur H. Elkind, MD
Mount Vernon, New York, United States, 10550